

Author Index for 1987

- Aalbers, C. 20:239, 22:127
Abrams, R. 20:57
Aceti, F. 20:207
Alessi, N.E. 20:275
Almay, B.G.L. 22:179
Amiri, Z. 21:221
Amsterdam, J.D. 20:325, 21:189
Angrist, B. 21:185
Ansseau, M. 22:193
Apelt, S. 22:303
Arató, M. 21:355
Arger, P. 21:189
Aryan, Z.S. 20:307
Asai, M. 21:49
Asnis, G. 20:79

Balon, R. 21:359, 22:37, 22:263
Barchas, J.D. 21:1, 22:21
Barksdale, C. 22:117
Bartkó, G. 22:221
Bartko, J.J. 20:165
Baumgartner, R. 20:33
Baxter, L.R., Jr. 21:237
Bellodi, L. 21:293
Benjamin, E. 22:257
Benkert, O. 20:177
Berchou, R. 21:359
Berenbaum, S.A. 20:57
Berg, L. 21:55
Berger, P.A. 20:47, 21:1, 22:21, 22:29
Berman, N. 20:1
Berman, S.R. 21:95
Berrettini, W.H. 22:141
Bigler, E.D. 22:91
Bochnik, H.J. 22:275
Boronow, J. 22:91
Borst, U. 22:331
Boulenger, J.-P. 21:247
Brambilla, F. 20:19
Breslau, N. 20:285
Brewerton, T.D. 21:213
Brochet, D.M. 21:267
Brody, D. 21:185
Brown, A. 22:261
Bruza, D. 22:261
Burns, E.M. 20:165, 22:229
Burrows, G.D. 22:43
Butters, N. 21:357
Byron, J.P., Jr. 20:261

Calderon, M. 20:33
Calil, H.M. 21:337
Campeas, R. 22:89

Candolfi, C. 20:19
Carpenter, W.T., Jr. 22:319
Carstens, M.E. 20:239, 22:127
Casper, R.C. 20:249
Cavagnini, F. 20:19
Cazzullo, C.L. 21:293
Cerfontaine, J.-L. 22:193
Chalton, D.O. 20:239, 22:127
Chamberlain, K.G. 20:199
Channabasavanna, S.M. 21:349
Charney, D.S. 21:33
Cherek, D.R. 21:257
Chrousos, G.P. 20:229
Climko, R. 20:261
Coccaro, E.F. 22:257
Codd, E.E. 22:61
Coffman, J.A. 22:229
Cohen, B.M. 20:107, 20:299
Cohen, M.R. 21:43
Cohen, R. 22:331
Cohn, B.S. 21:205
Cole, J.O. 20:143, 20:155
Comess, K.A. 20:13
Cooper, T.B. 20:313
Coromilas, J. 22:341
Coryell, W. 20:265
Coulter, M.E. 22:149
Cowley, D.S. 21:169
Csernansky, J.G. 20:47

Dackis, C.A. 20:261
Dager, S.R. 20:13, 21:169
Davidson, M. 20:307
Davies, B.M. 22:213
Davies, M. 22:341
Davis, G.C. 20:285
Davis, J.M. 20:165, 22:265
Davis, K.L. 20:307, 22:257
Dawson, G. 22:117
Delis, D.C. 21:357
DeLisi, L.E. 20:69
Demeter, E. 21:355
Demisch, L. 22:275
De Ruyter, M. 21:323
de Villiers, A.S. 22:127
Dillon, D.J. 20:97, 21:205
Dilsaver, S.C. 20:275
di Rosa, M. 21:293
Dixon, K.N. 20:189
Dobben, G.D. 20:165
Doran, A.R. 21:23
Dose, M. 22:303
Drinka, P.J. 21:199

- Droba, M. 20:325
 Dugger, D. 21:123
 Dunner, D.L. 21:13, 21:169
 Dupont, R.M. 21:357
 Dysken, M. 20:165

 Ebstein, R.P. 21:221
 Edell, W.S. 20:129
 Emrich, H.M. 22:303
 Engelbrecht, A.H. 20:239
 Erlenmeyer-Kimling, L. 22:159

 Fairbanks, L. 21:237
 Falus, A. 21:355
 Faull, K.F. 21:1, 22:21
 Fiume, S. 20:207
 Foa, E.B. 21:123
 Foreman, P.J. 22:69
 Fraioli, F. 20:207
 Frajese, G. 20:207
 Franck, G. 22:193
 Frazer, A. 20:1
 French, M.A. 20:199
 Frick, K. 20:117
 Friedhoff, A.J. 21:185
 Fuentesbro, F. 22:283
 Fujita, H. 21:285, 22:81
 Fulgham, J.R. 21:359
 Fyer, A.J. 20:97, 21:23, 21:205, 22:341

 Gagliano, C.A. 20:239, 22:127
 Galderisi, S. 21:137
 Gambini, O. 21:293
 Garbutt, J.C. 21:307
 Garnett, D. 21:89
 Garvey, M.J. 20:183
 Gebhart, P. 22:275
 Geenen, V. 22:193
 Gelenberg, A.J. 20:107
 George, D.T. 21:213
 Georgi, K. 22:275
 Gerbaldo, H. 22:275
 Gershon, E.S. 20:69
 Gillin, J.C. 20:181, 21:357
 Giordani, A.B. 20:307
 Glenn, M. 21:307
 Glover, V. 22:111
 Gold, M.S. 20:261
 Gold, P.W. 20:229
 Goldin, L.R. 20:69
 Goldstein, S. 20:79
 Goodman, S.I. 22:291
 Gorman, J.M. 20:97, 21:23, 21:205, 22:371
 Gottesman, I.I. 22:159
 Grabowski, J. 22:261

 Graziosi, S. 20:207
 Griez, E.J.L. 20:87
 Gross, H.S. 22:69
 Grossman, A. 22:207
 Guthrie, S. 21:161
 Gutman, R. 21:43
 Guze, B.H. 21:237

 Halbreich, U. 20:79
 Hama, Y. 21:285
 Hanin, I. 22:49
 Harrison, W. 21:9
 Heinrichs, D.W. 22:319
 Heninger, G.R. 21:33
 Herczeg, I. 22:221
 Hesselink, J.R. 21:357
 Himmelhoch, J.M. 22:49
 Hobin, P. 21:323
 Hoch, C.C. 21:95, 21:111
 Hollander, E. 22:89
 Hollifield, M. 21:313
 Holsboer, F. 20:83, 20:177
 Houck, P.A. 21:95
 Hsiao, J.K. 22:69
 Huggins, T. 22:11
 Hyde, T.S. 21:169

 Innis, R.B. 21:33
 Invitti, C. 20:19
 Ilio, M. 21:285, 22:81
 Irwin, M.R. 20:181, 22:283
 Ishii, T. 21:285, 22:81

 Jacobsen, F.M. 22:1
 James, S.P. 21:89
 Janicak, P.G. 22:265
 Javaid, J.I. 20:249
 Jernigan, T.L. 21:357
 Jimerson, D.C. 21:213
 Joffe, R.T. 21:71
 Jordan, R.C. 21:63
 Judd, F.K. 22:43

 Kaku, H. 21:229
 Kalin, N.H. 22:117
 Kanba, S. 21:49
 Kang, B.J. 20:79
 Kärkkäinen, J. 21:151
 Kartakis, D. 20:221
 Kathol, M.H. 22:229
 Katon, W.J. 21:313
 Kaufmann, C.A. 20:337
 Kelly, T.H. 21:257
 Kemali, D. 21:137
 Kempler, S. 22:311

- Khan, A. 20:13
 Khanna, S. 21:349
 Kimber, N.M. 22:43
 King, R.J. 21:1, 22:29
 Kishimoto, H. 21:285, 22:81
 Kitamura, T. 21:49
 Klar, H. 22:257
 Klein, D.F. 20:97, 21:23, 21:205, 22:341
 Kleinman, J.E. 22:291
 Knopf, S. 22:49
 Knowles, J.B. 22:149
 Korpi, E.R. 20:337, 22:291
 Koslow, S.H. 20:1
 Kozak, M.J. 21:123
 Kruckeberg, T.W. 22:229
 Kupfer, D.J. 21:95, 21:111
 Kuwahara, H. 21:285, 22:81
- Laatikainen, T. 21:151
 Lacoste, V. 21:181
 Lajtha, A. 20:313
 Lampertico, M. 20:19
 Langlais, P.J. 20:143, 20:155
 Legros, J.-J. 22:193
 Lerbinger, J.E. 20:143, 20:155
 Lerer, B. 21:221
 Levin, A.P. 21:23
 Levy, A.B. 20:189
 Liebowitz, M.R. 20:97, 21:23, 21:205, 22:89, 22:341
 Linnoila, M. 20:229, 21:161
 Loosen, P.T. 21:307
 Lousberg, H. 20:87
 Lykouras, L. 21:277
 Lynch, J.J. 22:69
- Macciardi, F. 21:293
 MacLean, A. 22:149
 Maddock, R.J. 22:29
 Maes, M. 21:323
 Maggioni, M. 20:19
 Magnani, A. 20:207
 Maguire, K.P. 22:213
 Magyar, K. 21:355
 Maislin, G. 20:325
 Maj, M. 21:137
 Malliaras, D. 21:277
 Mallinger, A.G. 22:49
 Mandal, M.K. 20:317
 Marangos, P.J. 21:247
 Marder, L.R. 20:215
 Marder, S.R. 22:283
 Marinelli, D.L. 21:189
 Markianos, M. 20:221
 Markowitz, J.S. 21:9
- Marnela, K.M. 20:337
 Martin, J.V. 21:89
 Martin, P. 21:267
 Masuda, Y. 21:49
 Matsushita, M. 21:285, 22:81
 Matussek, N. 21:85
 Maylath, E. 22:221
 Mazziotta, J.C. 21:237
 McAllister, D.A. 21:63
 McAmis, W. 21:43
 McCauley, R.B. 22:37
 McGrath, P.J. 21:9
 McIntyre, I.M. 22:43
 Melia, E. 20:207
 Meltzer, H.Y. 22:99
 Mendelson, W.B. 21:89
 Meyer, J.S. 20:129
 Miller, M.M. 20:143
 Milton, J. 21:89
 Mintz, M. 22:311
 Miyauchi, T. 21:285
 Mohs, R.C. 20:307
 Moldin, S.O. 22:159
 Morris, J.C. 21:55
 Moscovich, D. 21:221
 Moses, J.A., Jr. 22:29
 Müller, E.E. 20:19
 Müller-Oerlinghausen, B. 20:117
 Murchison, A. 22:29
 Mykytyn, V.V. 20:307
- Nakagawara, M. 21:85, 21:229
 Nasrallah, H.A. 21:303, 22:229
 Naukkarinen, H. 21:151
 Nemes, Z.C. 20:313
 Nerozzi, D. 20:207
 Nomura, Y. 21:285
 Norman, T.R. 20:199, 22:43
 Nurnberger, J.I., Jr. 22:141
- Ohno, S. 21:285, 22:81
 Orsulak, P.J. 20:183
 Oxenkrug, G.F. 22:37
- Palkovits, M. 21:355
 Pandey, G.N. 22:265
 Panerai, A.E. 20:19
 Papart, P. 22:193
 Patlak, C.S. 20:165
 Paul, S.M. 21:23
 Peabody, C.A. 21:1, 22:21
 Perel, J.M. 21:111
 Perri, M.G. 21:63
 Pettigrew, K.D. 20:165
 Phelps, M.E. 21:237

- Pickar, D. 20:229, 21:161, 22:91
 Pirozzi, R. 21:137
 Platt, S. 20:307
 Plutchik, R. 22:243
 Pohl, R. 21:359, 22:37, 22:263
 Post, R.M. 21:71, 22:11
 Prabucki, K. 20:285
 Prasad, A. 22:111
- Quitkin, F.M. 21:9
- Rabkin, J.G. 21:9
 Rai, A. 20:317
 Rainey, J.M. 21:359, 22:37
 Raisys, V. 20:13
 Rampling, R.P. 22:111
 Rauscher, F.P. 21:63
 Raz, N. 22:91
 Raz, S. 22:91
 Regier, D.A. 20:165
 Reynolds, C.F. III 21:95, 21:111
 Rimon, R. 21:151
 Robbins, D.R. 20:275
 Robinson, D. 21:257
 Rosenberg, S. 20:57
 Rosenthal, N.E. 22:1
 Roth, W.T. 22:29
 Rothschild, A.J. 20:143, 20:155
 Rotrosen, J. 21:185
 Rotter, A. 22:1
 Roy, A. 20:229, 21:161
 Roy-Byrne, P.P. 21:71
 Rubenstein, K. 22:257
 Rubin, E.H. 21:55
 Rubinow, D.R. 22:11
 Russell, V.A. 20:239, 22:127
 Ryan, J. 20:79
- Sacchetti, E. 21:293
 Sack, D.A. 21:89
 Sakellariou, G. 20:221
 Salem, N., Jr. 21:247
 Sali, L. 20:19
 Salminen, K. 21:151
 Salvati, A. 21:137
 Sandler, M. 22:111
 Sato, C. 21:285
 Sattin, A. 21:63
 Schatzberg, A.F. 20:143, 20:155
 Schildkraut, J.J. 20:155
 Schlemmer, R.F., Jr. 20:249
 Schmidt, H. 20:189
 Schweitzer, J. 21:185
 Secunda, S. 20:1
 Selin, C.E. 21:237
- Sershen, H. 20:313
 Sharpless, N. 20:79
 Shelton, S. 22:117
 Sherwood, P. 22:263
 Shima, S. 21:49
 Shimogawa, S. 21:229
 Siever, L.J. 22:257
 Sigal, M. 22:311
 Simmons-Alling, S. 22:141
 Simon, P. 21:267
 Sitaram, N. 22:261
 Skwerer, R.G. 22:1
 Smeraldi, E. 21:293
 Smith, R.C. 20:33
 Soubrie, P. 21:267
 Spoor, J. 21:151
 Stack, J.A. 21:95, 21:111
 Starace, F. 21:137
 Stefanis, C. 21:277
 Steiger, A. 20:177
 Steinberg, J.L. 21:257
 Steinman, R. 22:341
 Steketee, G. 21:123
 Stenman, U.-H. 21:151
 Stewart, J.W. 21:9
 Stieglitz, R.-D. 20:117
 Storandt, M. 21:55
 Sunderland, T. 20:299
 Surridge-David, M. 22:149
 Suy, E. 21:323
 Swann, A.C. 20:1
 Sweeney, D.R. 20:261
- Takahashi, R. 21:229
 Takazu, O. 21:285, 22:81
 Taljaard, J.J.F. 20:239, 22:127
 Tariot, P. 22:117
 Taylor, M.A. 20:57
 Tekes, K. 21:355
 Thase, M.E. 22:49
 Thiemann, S. 20:47
 Thienemann, M. 22:117
 Tiller, J.W.G. 22:213
 Timsit-Berthier, M. 22:193
 Tollefson, G.D. 20:183
 Tomer, R. 22:311
 Tóthfalusi, L. 21:355
 Tsichlakis, N. 20:221
 Tsukomo, T. 21:49
 Turkheimer, E. 22:91
 Turner, T.H. 22:207
- Uhde, T.W. 21:71, 21:247, 22:11
 Ulrich, G. 20:117
 Ur, E. 22:207


Valente, A. 21:137
 van den Hout, M.A. 20:87
 van der Molen, G.M. 20:87
 van Praag, H.M. 22:243
 Vassilopoulos, D. 21:277
 Veith, R.C. 21:313
 Villacres, E.C. 21:313
 Vita, A. 21:293
 Voeks, S.K. 21:199
 Volavka, J. 20:313
 von Frenckell, R. 22:193
 von Knorring, L. 22:179
 Voulgari, A. 21:277

 Wagman, A.M.I. 22:319
 Wagner, R. 21:89
 Walker, R.F. 22:61
 Warner, M.D. 22:21
 Watanabe, A. 21:229
 Wehr, T.A. 21:89
 Weiler, S. 22:117
 Weinberger, D.R. 20:337, 22:91
 Wetterberg, L. 22:179

Whiteford, H.A. 21:1, 22:21
 Wiedemann, K. 20:83
 Wilcox, J.A. 21:303
 Wilkinson, C.W. 21:313
 Winokur, A. 20:325, 21:189
 Wirz-Justice, A. 21:181
 Witzke, W. 21:85
 Wolfe, N. 20:107
 Woods, D.J. 20:215
 Wyatt, R.J. 22:291

 Yamaguchi, T. 22:81
 Yehuda, R. 20:129
 Yeragani, V.K. 21:359, 22:37, 22:263
 Yokoi, S. 21:285, 22:81
 Yoshimoto, S. 21:229
 Yuwiler, A. 22:283

 Zeevi, S. 21:221
 Zimmer, B. 21:111
 Zimmerman, M. 20:265
 Zureick, J.L. 22:99
 Zwicker, A.P. 21:337



Subject Index for 1987

- Adenosine
 caffeine in plasma, anxiety, 21:247
- Adenylate cyclase
 lithium, platelet, 21:221
- α_2 -Adrenoceptor
 affective disorder, platelet, 22:127
 affective illness, yohimbine in platelets, 20:107
 panic disorder, rauwolscine binding, 22:43
- β -Adrenoceptor
 affective disorder, lymphocyte binding, 20:239
 affective disorder, platelet, 22:127
 leukocyte membrane, cyanopindolol, 22:265
 schizophrenia, affective disorders, 22:265
- Adrenocorticotrophic hormone
 cortisol, affective illness, 20:325, 22:117
 lactate induced panic, 21:23
- Affective disorder
 adrenal gland volume, computed tomography, 21:189
 α_2 -adrenoceptor, platelets, 20:107, 22:127
 β -adrenoceptor binding, dexamethasone suppression test, 22:265
 β -adrenoceptor binding, severity, 20:239, 22:127
 adrenocorticotrophic hormone, dexamethasone suppression, 20:235, 22:117
 amino acids in serum, dexamethasone suppression test, 21:323
 apomorphine, growth hormone, 22:193
 arachidonic acid, platelet membrane phospholipid incorporation, 22:275
 arecoline infusion, sleep, 22:261
 bipolar disorder, growth hormone releasing factor, 22:141
 bipolar disorder, growth hormone response to clonidine, 22:193
 bipolar disorder, sodium transport, 22:49
 bipolar/unipolar, Minnesota Multiphasic Personality Inventory, 22:159
 bipolar/unipolar, norepinephrine, 21:161
 bipolar/unipolar, panic attack incidence, 20:183
 bipolar/unipolar, positron emission tomography, 22:81
 blood pressure, clonidine and apomorphine response, 22:193
- Affective disorder (cont.)
 blood pressure, endogenous subtype, 21:85
 calcium in serum, anxiety, 22:29
 carbamazepine, family history, 21:71
 carbamazepine, sleep deprivation, 22:11
 catecholamines, dexamethasone, 20:143, 22:21, 22:127
 circadian rhythm, plasma 3-methoxy-4-hydroxyphenylglycol, 20:79
 clonidine, growth hormone, 22:193
 corticotropin releasing hormone, affective illness, 20:229
 cortisol, catecholamines, 20:143, 22:21, 22:127
 cortisol, electroconvulsive therapy and naloxone, 22:207
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 22:127
 cortisol, naloxone effect, 22:207
 cortisol response to adrenocorticotrophic hormone, 20:235, 22:117
 cortisol, serum amino acids, 21:323
 delusional depression, family study, 21:277
 dementia, antidepressants, 21:111
 depression assessment, comparison of five self-report scales, 22:243
 depression, Plutchik-van Praag self-report scale, 22:243
 dexamethasone, cortisol, 20:143, 22:21, 22:117
 dexamethasone, β -endorphin, 21:151
 dexamethasone in plasma, cortisol suppression, 20:83
 dexamethasone suppression test, β -adrenoceptor binding, 22:P5
 dexamethasone suppression test, adrenocorticotrophic hormone, 22:117
 dexamethasone suppression test, melancholic subgroups, 20:235
 dexamethasone suppression test, norepinephrine, 21:161
 dexamethasone suppression test, serum amino acids, 21:323
 dexamethasone suppression, thyroid stimulating hormone, 22:21, 22:127
 dexamethasone suppression, urinary catecholamines, 20:229
 dopamine in plasma, psychotic depression, 20:143

Affective disorder (cont.)

- electroconvulsive therapy, carbamazepine, 22:11
- electroconvulsive therapy frequency, 21:63
- electroconvulsive therapy, naloxone neuroendocrine effect, 22:207
- electroconvulsive therapy, thyroid-stimulating hormone, 20:207
- emotional blunting, factor analytic study, 20:57
- β -endorphin, dexamethasone, 21:151
- familial subtypes, 3-methoxy-4-hydroxyphenylglycol, 22:117
- family history, carbamazepine response, 21:71
- fenfluramine response, prolactin 22:257
- frontal lobe, positron emission tomography, 22:81
- generalized anxiety disorder, mothers' illness, 20:285
- glucose in serum, anxiety, 22:29
- growth hormone, clonidine response, 22:193
- growth hormone, electroconvulsive therapy and naloxone, 22:207
- growth hormone releasing factor, lithium, 22:141
- head trauma, bipolar/depressive 21:303
- homovanillic acid, thyroid-stimulating hormone, 22:21
- hyperventilation, serum phosphate, 22:29
- hypothyroidism, depressive symptoms, 21:199
- imipramine binding, platelet, 21:33
- immune cell function, natural killer cell activity, 20:181
- light therapy, mood effect, 22:1
- lithium distribution, mania, 20:1
- lithium effect, sodium transport, 22:49
- lithium, growth hormone releasing factor, 22:141
- magnetic resonance imaging, bipolars, 21:357
- mania, growth hormone response to clonidine and apomorphine, 22:193
- membrane potential, lithium effect, 22:49
- 3-methoxy-4-hydroxyphenylglycol, circadian rhythm, 20:79
- 3-methoxy-4-hydroxyphenylglycol, panic attacks, 20:183
- 3-methoxy-4-hydroxyphenylglycol, thyroid-stimulating hormone, 22:21, 22:127

Affective disorder (cont.)

- Minnesota Multiphasic Personality Inventory, 22:159
 - monoamine metabolites, red blood cell/lithium ratio, 20:1
 - monoamine oxidase inhibitors, social behavior, 22:89
 - naloxone, electroconvulsive therapy, 22:207
 - norepinephrine, cold challenge, 21:161
 - norepinephrine in plasma, cortisol, 22:117
 - opioids, electroconvulsive therapy, 22:207
 - panic disorders, adolescents, 20:275
 - phosphate serum levels, anxiety, 22:29
 - phospholipids, arachidonic acid incorporation, 22:275
 - placebo response, antidepressants, 21:9
 - positron emission tomography, bipolar/unipolar, 22:81
 - prolactin, electroconvulsive therapy and naloxone, 22:207
 - prolactin response, fenfluramine, 22:257
 - psychotic depression, plasma dopamine, 20:143
 - secondary depression, thyroid-stimulating hormone, 22:21
 - self-report scales, development and methodology, 22:243
 - serotonin reuptake inhibitors, fenfluramine, 22:257
 - severity, β -adrenoceptor binding, 20:239
 - severity, dopamine in plasma, 20:143
 - severity, rapid eye movement sleep, 20:189
 - severity, thyroid-stimulating hormone, 22:21
 - sleep, arecoline infusion, 22:261
 - sleep deprivation, carbamazepine, 22:11
 - sleep deprivation, older endogenous depression, 21:95
 - sleep, frequency analysis of electroencephalogram, 21:89
 - sleep variables, polysomnography 20:189
 - sodium transport, lithium effect, 22:49
 - suicidal thoughts, 5-hydroxy-indoleacetic acid, 21:1
 - suicide, delusional depression, 21:277
 - thyroid-stimulating hormone, depressive symptoms, 21:199
 - thyroid-stimulating hormone, electroconvulsive therapy, 20:207
 - thyroid-stimulating hormone, 3-methoxy-4-hydroxyphenylglycol, 22:21
- Age
- α_2 -adrenoceptors in platelets, affective illness 20:107

Age (cont.)

- anxiety, caffeine in plasma, 21:247
- cortisol, affective illness, 20:143, 20:155
- dopamine in plasma, affective illness, 20:143
- dopamine- β -hydroxylase, 20:221
- melatonin, chronic pain, 22:179

Aggressive behavior

- amphetamine, laboratory response, 21:257

Alcoholism

- perceptual aberration scale, monoamine oxidase, 20:129
- reaction time, evoked potentials, 22:85
- thyroid-stimulating hormone, secondary depression, 22:21

Alzheimer's dementia

- antidepressant treatment, 21:111
- personality change, factor structure, 21:55

Amino acids

- brains post-mortem, schizophrenia, 22:291
- dexamethasone suppression test, affective disorder, 21:323
- schizophrenia, levels in cerebrospinal fluid, 20:337

Amphetamine

- aggressive behavior, button press response, 21:257
- psychosis induction, 5-hydroxy-tryptophan, 22:283

Anorexia nervosa

- clonidine, growth hormone response, 20:19
- clonidine treatment, 3-methoxy-4-hydroxyphenylglycol, 20:249
- β -endorphin, desmethylimipramine response, 20:19
- rapid eye movement sleep, concurrent depression, 20:189

Antidepressants

- carbamazepine response, sleep deprivation and electroconvulsive therapy, 22:11
- dementia treatment in elderly, 21:111
- lactate panic, hyperventilation 21:205
- monoamine oxidase inhibitors, social behavior, 22:89
- placebo response, 21:9
- sleep deprivation, prolactin and growth hormone, 21:337
- triiodothyronine potentiation, learned helplessness, 21:267

Apomorphine

- growth hormone response, affective disorder, 22:193

Arachidonic acid

- membrane phospholipids, schizophrenia, 22:275

Arecoline

- rapid eye movement sleep, affective illness, 22:261

Attention

- electroencephalogram, lithium, 20:117
- negative symptoms, schizophrenia, 20:47

Blood pressure

- anorexia nervosa, clonidine, 20:19
- clonidine, anorexia nervosa, 20:249
- clonidine and apomorphine response, affective disorder, 22:193
- endogenous/nonendogenous diagnosis, 21:85
- lactate infusion, bulimia, 21:213
- lactate infusion, panic disorder, 21:169, 22:263
- mitral valve prolapse, panic disorder, 20:13
- panic disorder, plasma norepinephrine, 21:313
- schizophrenia, speaking, 22:69

Blood-brain barrier

- dynamic computed tomography, schizophrenia, 22:229

Borderline personality disorder

- prolactin, cortisol and T_3 , 21:307
- thyroid-stimulating hormone, haloperidol treatment, 21:307

Brain structure

- magnetic resonance imaging, schizophrenia, 20:33

Brofaremine

- rapid eye movement sleep, 20:177

Bromocriptine

- cocaine craving reversal, 20:261

Bulimia. *See also* Anorexia nervosa

- lactate induced panic, 21:213
- sleep recording, depression type, 20:189

Caffeine

- adenosine in plasma, anxiety, 21:247

Calcium

- affective disorder, serum levels, 22:29

Cancer

- monoamine oxidase in platelets, depression, 22:111

Carbamazepine

- mania response, family history, 21:71
- response rate compared to sleep deprivation, 22:11

- Carbamazepine**
schizophrenia, clinical response, 22:D5
- Carbidopa**
homovanillic acid, lack of effect, 21:185
- Carbon dioxide**
panic disorder, inhalation, 20:87
- Catecholamines**
corticotropin-releasing hormone, affective disorder, 20:229
depression severity, cerebrospinal fluid levels, 21:1
dexamethasone, affective illness, 20:143
growth hormone response to clonidine and apomorphine, 22:193
lithium treatment, red blood cell ratio, 20:1
monoamine oxidase, affective symptoms, 20:155
panic disorder, mitral valve prolapse, 20:13
- Childhood disorders**
generalized anxiety disorder, over-anxious disorder, 20:285
panic disorder, concurrent depression, 20:275
- Circadian rhythms**
light therapy, mood change, 22:1
3-methoxy-4-hydroxyphenylglycol, affective illness, 20:79
sleep phase shift, mood in normals, 22:149
- Circannual rhythm**
diurnal mood variation, 21:181
imipramine binding, affective disorder, 21:33
light therapy, seasonal affective disorder, 22:1
personality dimensions, 21:181
placebo response, antidepressants, 21:9
- Clonidine**
anorexia nervosa, growth hormone and desmethylimipramine, 20:19
anorexia nervosa, 3-methoxy-4-hydroxyphenylglycol, 20:249
growth hormone response, affective disorder, 22:193
- Cocaine**
bromocriptine reverses craving, 20:261
- Computed tomography**
adrenal gland volume, 21:189
blood-brain barrier, schizophrenia, 22:229
contrast material time-density curves, schizophrenia, 20:165
schizophrenia, third ventricle enlargement, 21:49
- Computed tomography (cont.)**
ventricular size, methodological review, 22:91
- Corticotropin releasing hormone**
norepinephrine, affective disorder, 20:229
- Cortisol**
 β -adrenoceptor binding, schizophrenia and affective disorder, 22:265
adrenocorticotrophic hormone effect, affective illness, 20:235, 22:117
affective illness, dexamethasone, 20:143, 20:155
amino acids in serum, affective illness, 21:323
anorexia nervosa, clonidine and desmethyl-imipramine, 20:19
borderline personality disorder, 21:307
 β -endorphin, dexamethasone, 21:151
lactate induced panic, 21:23
monoamine oxidase in platelet, 20:155
naloxone and electroconvulsive therapy, 22:207
norepinephrine, affective illness, 22:127
- Cyanopindolol**
leukocyte membrane binding, affective disorder and schizophrenia, 22:265
- Cyclic adenosine monophosphate**
lithium adenylate cyclase in platelet, 21:221
- Dementia**
antidepressant treatment in elderly, 21:111
- Desipramine**
anorexia nervosa, weight, 20:19
cortisol, clonidine, 20:19
growth hormone, β -endorphin, 20:19
sleep deprivation, prolactin and growth hormone, 21:337
- Dexamethasone**
adrenocorticotrophic hormone effect, cortisol, 20:235
cortisol suppression, plasma level, 20:83
- Dexamethasone suppression test**
 β -adrenoceptor binding, affective disorder, 20:239, 22:265
 β -adrenoceptor binding, schizophrenia, 22:265
adrenocorticotrophic hormone, affective illness, 22:117
amino acids in serum, affective disorder, 21:323
catecholamines in plasma, psychotic depression, 20:143
corticotropin-releasing hormone, norepinephrine, 20:229
cortisol, 3-methoxy-4-hydroxyphenylglycol, 22:127

- Dexamethasone suppression test (cont.)
 β -endorphin and β -lipotropin, cortisol, 21:151
 family history of affective illness, 20:265
 norepinephrine, cold challenge, 21:161
 thyroid-stimulating hormone, affective illness, 22:21
- Diagnosis
 Diagnostic Inventory Schedule for Children, 20:285
 generalized anxiety disorder, validity, 20:285
 Minnesota Multiphasic Personality Inventory, diagnostic validation, 22:159
 panic disorder and concurrent depression in adolescents, 20:275
- Dihydroalprenolol
 lymphocyte binding, affective disorder, 20:239
- Dopamine
 affective illness, dexamethasone, 20:143, 20:155
- Dopamine- β -hydroxylase
 schizophrenia, family study, 20:221
- Electroconvulsive therapy
 carbamazepine, sleep deprivation, 22:11
 dementia, 21:111
 naloxone, growth hormone and prolactin, 22:207
 prolactin and thyroid-stimulating hormone, 20:207
 treatment frequency, 21:63
- Electroencephalogram
 frequency analysis, sleep, 21:89
 lithium, normal controls, 20:117
 sleep, affective illness, 21:89
 ventricular enlargement, frequency analysis in schizophrenia, 21:137
- β -Endorphin
 anorexia nervosa, clonidine, 20:19
- Epinephrine
 affective illness, dexamethasone, 20:143, 20:155
 anxiety ratings, panic disorder, 21:313
- Evoked potentials
 contingent negative variation, schizophrenia and alcoholism, 22:331
 neuroleptic side effects, hemispheric asymmetry, 22:311
- Eye movements
 lateralization, schizophrenia, 20:215
 smooth pursuit, schizophrenia, 21:293
- Fenfluramine
 prolactin response, affective disorder, 22:257
- Frontal lobe
 amino acids, post-mortem brain in schizophrenia, 22:291
 blood-brain barrier permeability, hypofrontal pattern, 22:229
 glucose metabolic rate, affective disorder, 22:81
- Generalized anxiety disorder
 diagnostic validity, family study, 20:285
- Genetics
 delusional depression, multifactorial inheritance, 21:277
 dexamethasone suppression, family history of affective illness, 20:265
 dopamine- β -hydroxylase, schizophrenia, families, 20:221
 generalized anxiety disorder, mother's illness, 20:285
 human leukocyte antigens, schizophrenia, 20:69
 3-methoxy-4-hydroxyphenylglycol, familial subtypes of affective illness, 22:117
- Glucose
 phosphate serum level, affective illness, 22:29
 positron emission tomography, affective disorder, 22:81
 positron emission tomography, schizophrenia, 21:285
 positron emission tomography, sex differences in metabolic rate, 21:237
- Growth hormone
 anorexia nervosa, clonidine and desmethyl-imipramine, 20:19
 clonidine and apomorphine response, affective disorder, 22:193
 naloxone and electroconvulsive therapy, 22:207
 sleep deprivation, desimipramine treatment, 21:337
- Growth hormone releasing factor
 bipolar affective disorder, lithium effect, 22:141
- Heart rate
 clonidine, anorexia nervosa, 20:249
 lactate infusion, panic disorder, 22:341
 mitral valve prolapse, panic disorder, 20:13
 panic disorder, plasma norepinephrine, 21:313
 schizophrenia, speaking, 22:69

- Heart rate (cont.)**
 sleep infusion of arecoline, affective illness, 22:261
- Hemispheric asymmetry (see Laterality)**
- Homovanillic acid**
 carbidopa effect, normal controls, 21:185
 depression, cerebrospinal fluid level, 21:1
 diet and physical activity, 20:307
 lithium distribution, mania, 20:1
 smoking, normal controls, 20:307
 thyroid stimulating hormone, affective illness, 22:21
- Human leukocyte antigens**
 schizophrenia, chromosome 6, 20:69
- 5-Hydroxyindoleacetic acid**
 brains of suicides, 21:355
 depression, cerebrospinal fluid level, 21:1
 lithium distribution, mania, 20:1
- 5-Hydroxytryptamine**
 brains of suicides, 21:355
- 5-Hydroxytryptophan**
 amphetamine induced psychosis, schizophrenia, 22:283
- Imipramine**
 obsessive-compulsive disorder treatment, 21:123
- Imipramine binding**
 affective illness and panic disorder, 21:33
 brains of suicides, platelet binding, 21:355
 circannual variation, 21:33
- Immune function**
 affective illness, natural killer cells, 20:181
- Isoproterenol**
 blood pressure, panic disorder, 22:263
- Lactate**
 adrenocorticotrophic hormone, cortisol, 21:23
 antidepressants, panic, 21:205
 blood pressure, panic disorder, 22:263
 bulimia, anxiety, 21:213
 gravity feed administration, 21:359
 heart rate, panic disorder, 22:341
 panic attacks, baseline blood pressure, 21:169
 panic disorder, agoraphobia, 20:97
- Laterality**
 brains of suicides, serotonergic function, 21:355
 clockwise circling, schizophrenia, 20:215
 evoked potentials, neuroleptic side effects, 22:311
- Learned helplessness**
 triiodothyronine, antidepressant interaction, 21:267
- Life events**
 schizophrenia, relapse off medication, 22:221
- Light**
 treatment, depression change, 22:1
- β -lipotropin**
 dexamethasone, cortisol, 21:151
- Lithium**
 adenylate cyclase, platelet, 21:221
 electroencephalogram, normals, 20:117
 growth hormone releasing factor, bipolars, 22:141
 neuroleptic levels in brain and plasma, 20:313
- Lithium (cont.)**
 red blood cell ratio, monoamine metabolites, 20:1
 sodium transport, red blood cell, 22:49
- Magnetic resonance imaging**
 bipolar affective illness, subcortical signal hyperintensities, 21:357
 schizophrenia, ventricular size and image intensity, 20:33
- Melatonin**
 pain syndromes, depressive symptoms, 22:179
- Membrane transport**
 sodium transport, bipolar affective disorder, 22:49
- Memory**
 electroconvulsive therapy, 21:63
- Metanephrine**
 lithium distribution, mania, 20:1
- 3-Methoxy-4-hydroxyphenylglycol**
 anorexia nervosa, clonidine treatment, 20:249
 circadian rhythm, affective illness, 20:79
 corticotropin-releasing hormone, dexamethasone suppression test, 20:229
 cortisol, thyroid stimulating hormone, 22:127
 depression, cerebrospinal fluid level, 21:1
 lithium distribution, mania, 20:1
 mitral valve prolapse, panic disorder, 20:13
 panic attacks, depressed patients, 20:183
 red blood cell/lithium ratio, mania, 20:1
 thyroid-stimulating hormone, affective illness, 22:21
- Mitral valve prolapse**
 panic disorder, catecholamines, 20:13
- Moclobemide**
 tyramine-pressor response, clinical response, 22:213

Monoamine oxidase

- cancer, depression, 22:111
- Hamilton Rating Scale for Depression, items, 20:155
- mitral valve prolapse, panic disorder, 20:13
- panic disorder, platelets, 22:37
- paranoia, schizophrenia, 22:99
- psychosis proneness, college students, 20:129
- psychotic depression, plasma catecholamines, 20:155
- race, gender, 22:99
- schizophrenia, auditory hallucinations, 22:99
- schizophrenia, β -phenylethylamine, 21:229
- smoking, normals, 20:199

Monoamine oxidase inhibition

- rapid eye movement sleep, 20:177
- social behavior, affective illness, 22:89
- tyramine-pressor response, 22:213

Naloxone

- electroconvulsive therapy, growth hormone and prolactin, 22:207

Neuroleptics

- brain distribution, rat, 20:299
- brain and plasma levels, lithium effect, 20:313
- carbamazepine combined with haloperidol, 22:303
- dopamine- β -hydroxylase, dose, 20:221
- β -endorphin, dexamethasone, 21:151
- evoked potentials, lateralized side effects, 22:311
- lateralized side effects, evoked potential hemispheric asymmetry, 22:311
- life events, relapse, 22:221
- thyroid-stimulating hormone, borderline personality disorder, 21:307

Norepinephrine

- affective illness, dexamethasone, 20:143, 20:155
- cold challenge, affective illness, 21:161
- corticotropin releasing hormone, affective illness, 20:229
- cortisol, affective illness, 22:127
- isotope dilution kinetics, 21:313
- lithium distribution, mania, 20:1

Normal values

- adrenal gland volume, CT scan, 21:189
- amino acids, brains, 22:291
- arachidonic acid incorporation, platelet membrane phospholipids, 22:275

Normal values (cont.)

- cortisol, dexamethasone, 20:143
- cortisol, plasma, 22:127
- cortisol, plasma, clonidine response, 20:19
- dexamethasone suppression test, 20:265
- dopamine, plasma, dexamethasone, 20:143
- electroencephalogram, lithium, 20:117
- β -endorphin, β -lipotropin, plasma, 21:151
- β -endorphin, plasma, clonidine stimulation, 20:19
- epinephrine, dexamethasone, 20:143
- growth hormone, clonidine response, 20:19
- growth hormone releasing factor, cerebrospinal fluid, 22:141
- imipramine binding, platelet, 21:33
- melatonin, serum and urine, 22:179
- 3-methoxy-4-hydroxyphenylglycol, plasma, 22:127
- monoamine oxidase, platelets, 20:129, 22:27, 22:99
- norepinephrine, dexamethasone, 20:143
- norepinephrine, plasma, 22:127
- rauwolscine binding in platelet, 22:43
- sleep, EEG frequency analysis, 21:89
- smooth pursuit eye movements, 21:293
- ventricular size, magnetic resonance imaging, 20:33
- yohimbine binding, platelet, 20:107
- Normetanephrine**
 - corticotropin-releasing hormone, affective illness, 20:229
 - lithium distribution, mania, 20:1
- Obsessive-compulsive disorder**
 - birth order, family size 21:347
 - imipramine response, 21:123
- Opioids**
 - naloxone, electroconvulsive therapy, 22:207
- Outcome**
 - emotional blunting, treatment response, 20:57
 - red blood cell/lithium ratio, 20:1
- Pain syndromes**
 - melatonin, neurogenic pain syndrome, 22:179
- Panic disorder**
 - adolescents, concurrent depressive disorders, 20:275
 - α_2 -adrenoceptor binding, platelet, 22:43
 - adrenocorticotrophic hormone, lactate administration, 21:23

- Panic disorder (cont.)**
 blood pressure, lactate panic, 21:169, 22:263
 catecholamines, cardiovascular measures, 20:13
 CO₂ inhalation, panic provocation, 20:87
 cortisol, lactate effect, 21:23
 epinephrine, anxiety ratings, 21:313
 heart rate, lactate infusion, 22:341
 lactate, blood pressure, 22:263
 lactate infusion, 20:97
 imipramine binding, platelet, 21:33
 3-methoxy-4-hydroxyphenylglycol, depressed patients, 20:183
 mitral valve prolapse, platelet monoamine oxidase, 20:13
 monoamine oxidase in platelets, 22:37
 norepinephrine kinetics, 21:313
 psychoactive medication, lactate panic, 21:205
- Phenylacetic acid**
 schizophrenia, monoamine oxidase, 21:229
- β -Phenylethylamine**
 schizophrenia, monoamine oxidase, 21:229
- Phosphate**
 affective disorder, serum levels, 22:29
- Phospholipids**
 arachidonic acid incorporation, platelet membranes, 22:275
- Platelets**
 adenylate cyclase, lithium, 21:221
 arachidonic acid incorporation, membrane phospholipids, 22:275
 imipramine binding, affective illness, 21:33
 monoamine oxidase, mitral valve prolapse, 20:13
 monoamine oxidase, panic disorder, 22:37
 monoamine oxidase, psychosis proneness, 20:129
 monoamine oxidase, psychotic depression, 20:155
 monoamine oxidase, schizophrenia, 21:229
 rauwolscine binding, panic disorder, 22:43
 serotonin uptake, rat strain differences, 22:61
 yohimbine binding, affective disorder, 20:107
- Positron emission tomography**
 bipolar and unipolar affective disorder, 22:81
- Positron emission tomography (cont.)**
 schizophrenia, frontal and parietal lobes, 21:285
 sex differences, glucose, metabolic rate, 21:237
- Prolactin**
 borderline personality disorder, haloperidol, 21:307
 electroconvulsive therapy and thyroid-stimulating hormone, 20:207
 fenfluramine response, affective disorder, 22:257
 naloxone, electroconvulsive therapy, 22:207
 sleep deprivation, desipramine treatment, 21:337
- Race**
 schizophrenia, auditory hallucinations, 22:99
- Red blood cell**
 lithium ratio, monoamine metabolites, 20:1
- Rapid eye movement sleep (see Sleep)**
- Rauwolscine**
 panic disorder, platelet binding, 22:43
- Reaction time**
 cross-over effect, schizophrenia, 22:331
- Red blood cell**
 sodium transport, lithium effect, 22:49
- Scales**
 Acute Panic Inventory, lactate infusions, 20:97, 21:169, 21:205
 Beck Depression Inventory, β -adrenoceptor, 20:239
 Beck Depression Inventory, correlation with four self-report scales, 22:243
 Beck Depression Inventory, obsessive-compulsive disorder, 21:123
 Blessed Dementia, Alzheimer's dementia, 21:55
 Blessed Dementia, antidepressant response, 21:111
 Brief Psychiatric Rating Scale, carbamazepine response, 22:303
 Brief Psychiatric Rating Scale, life events, 22:221
 Brief Psychiatric Rating Scale, negative symptoms, 20:47
 Center for Epidemiological Studies—Depression Questionnaire, correlation with four self-report scales, 22:243
 Compulsive Activity Checklist, imipramine response, 21:123
 Emotional Blunting Scale, schizophrenia and affective illness, 20:57
 Folstein Mini-Mental, antidepressants in elderly, 21:111
 Geriatric Depression Scale, hypothyroidism, 21:199

Scales (cont.)

- Hamilton Rating Scale for Anxiety, platelet monoamine oxidase, 22:111
- Hamilton Rating Scale for Depression, adolescent/panic disorder, 20:275
- Hamilton Rating Scale for Depression, α_2 -adrenoceptor affinity, 20:107
- Hamilton Rating Scale for Depression, β -adrenoceptor binding, 20:239
- Hamilton Rating Scale for Depression, cerebrospinal fluid amine metabolites, 21:1
- Hamilton Rating Scale for Depression, electroconvulsive therapy, 20:207
- Hamilton Rating Scale for Depression, light treatment, 22:1
- Hamilton Rating Scale for Depression, monoamine oxidase 20:155
- Hamilton Rating Scale for Depression, phosphate and calcium, 22:29
- Hamilton Rating Scale for Depression, rapid eye movement sleep, 20:189
- Hamilton Rating Scale for Depression, sleep deprivation, 21:95
- Hamilton Rating Scale for Depression, thyroid-stimulating hormone, 22:21
- Inpatient Multidimensional Rating Scale, carbamazepine response, 22:303
- Manic Diagnostic and Severity Scale, lithium, 20:1
- Maudsley Obsessional-Compulsive Inventory, 21:123
- Minnesota Multiphasic Personality Inventory, diagnostic validation, 22:159
- Minnesota Multiphasic Personality Inventory, serum phosphate, 22:29
- Minnesota Multiphasic Personality Inventory D Scale, correlation with four self-report scales, 22:243
- Montgomery-Asberg Depression Scale, platelet monoamine oxidase, 22:111
- Perceptual Aberration Scale, platelet monoamine oxidase, 20:129
- Physical Anhedonia Scale, platelet monoamine oxidase, 20:129
- Plutchik-van Praag Self-Report Depression Scale, criteria for depression, 22:293
- Profile of Mood States, sleep deprivation, 21:95
- Scale for Assessment of Negative Symptoms, redundant measures, 20:47

Scales (cont.)

- Spielberger Anxiety Rating, bulimia, 21:213
- Spielberger Anxiety Rating, imipramine response, 21:123
- Spielberger Anxiety Rating, plasma caffeine, 21:247
- Stanford Sleepiness Scale, sleep deprivation, 22:149
- Subjective Units of Disturbance, anxiety, 20:87
- Wechsler Adult Intelligence Scale, ventricular enlargement, 21:137
- Wechsler Rating Scale for Depression, 20:19
- Zung Depression Scale, anorexia nervosa, 20:19
- Zung Depression Scale, comparison with four self-report scales, 22:243
- Zung Anxiety Rating, plasma caffeine, 21:247
- Schizophrenia
 - β -adrenoceptor binding, dexamethasone suppression test, 22:265
 - affect in facial emotion, photo judgment, 20:317
 - amino acids, cerebrospinal fluid, 20:337
 - amino acids, post-mortem brain, 22:291
 - γ -aminobutyric acid (GABA), post-mortem brain, 22:291
 - amphetamine induction of psychosis, 5-hydroxytryptophan, 22:283
 - auditory hallucinations, platelet-monoamine oxidase, 22:99
 - blood-brain barrier permeability, dynamic computed tomography, 22:229
 - blood pressure, speaking, 22:69
 - carbamazepine, clinical response, 22:303
 - computed tomography, blood-brain barrier permeability, 22:229
 - computed tomography, contrast material time density curves, 20:165
 - computed tomography, methodology, 22:91
 - contingent negative variation, reaction time, 22:331
 - cross-over effect, evoked potentials, 22:331
 - deficit syndrome, neuropsychological impairment, 22:319
 - dexamethasone suppression test, β -adrenoceptor binding, 22:265
 - dopamine- β -hydroxylase, family studies, 20:221
 - educational level, deficit syndrome, 22:319
 - electroconvulsive therapy, thyroid-stimulating hormone, 20:207

Schizophrenia (cont.)

- electroencephalogram, ventricular enlargement, 21:137
- emotional blunting, factor analytic study, 20:57
- employment status, blood pressure, 22:69
- evoked potentials, hemispheric asymmetry, 22:311
- evoked potentials, reaction time, 22:331
- eye movements, lateralization, 20:215
- eye movements, ventricle size, 21:293
- facial emotion judgments, 20:317
- fibroblasts, growth and response to toxic oxygen metabolites, 21:43
- frontal lobe, blood-brain barrier permeability, 22:229
- frontal white matter, magnetic resonance image, 20:33
- hallucinations, platelet monoamine oxidase, 22:99
- head trauma history, 21:303
- heart rate, speaking, 22:69
- high risk sample, Minnesota Multiphasic Personality Inventory, 22:159
- human leukocyte antigens, chromosome 6, 20:69
- 5-hydroxytryptophan, amphetamine induction of psychosis, 22:283
- hypofrontality, dynamic computed tomography, 22:229
- hypofrontality, positron emission tomography, 21:285
- laterality, blood-brain barrier permeability, 22:229
- laterality, clockwise circling, 20:215
- lateralized neuroleptic side effects, evoked potentials, 22:311
- life events, relapse, 22:221
- Luria-Nebraska Neuropsychological Battery, ventricular enlargement, 21:137
- magnetic resonance imaging, image intensity, 20:33
- Minnesota Multiphasic Personality Inventory, diagnosis, 22:159
- monoamine oxidase in platelet, auditory hallucinations, 22:99
- monoamine oxidase in platelets, psychosis proneness, 20:129
- monoamine oxidase, urinary phenylethylamine, 21:229
- negative symptoms, neuropsychological impairment, 22:319
- negative symptom measurement, 20:47
- negative symptoms, ventricular enlargement, 21:137

Schizophrenia (cont.)

- neuroleptics, relapse and life events, 22:221
- neuropsychological impairment, deficit syndrome, 22:319
- paranoid type, phenylethylamine in urine, 21:229
- paranoid type, platelet monoamine oxidase, 22:99
- phenylacetic acid, platelet monoamine oxidase, 21:229
- phenylethylamine, platelet monoamine oxidase, 21:229
- positron emission tomography, 21:285
- prolactin, electroconvulsive therapy, 20:207
- race, platelet monoamine oxidase, 22:99
- reaction time cross-over effect, evoked potentials, 22:331
- relapse, life events, 22:221
- schizoaffective disorder diagnosis, high-risk sample, 22:159
- schizophreniform, arachidonic acid incorporation, 22:275
- serotonin, psychosis induction by amphetamine, 22:283
- sex differences, platelet monoamine oxidase, 22:99
- speaking, cardiovascular response, 22:69
- ventricular enlargement, smooth pursuit eye movements, 21:293
- ventricular enlargement, Wechsler Adult Intelligence Scale, 21:137
- ventricular size, 20:33, 21:49
- ventricular size, methodological review, 22:91
- tardive dyskinesia, evoked potentials, 22:311
- Seasonal affective disorder
 - light treatment, mood change in normals, 22:1
- Serotonin
 - amphetamine induced psychosis, 5-hydroxytryptophan, 22:283
 - platelet uptake, methods and rat-strain differences, 22:61
 - prolactin response to fenfluramine, affective disorder, 22:257
- Sex differences
 - dopamine- β -hydroxylase, schizophrenia, 20:221
 - lactate response, panic disorder, 22:341
 - glucose metabolic rate, positron emission tomography, 21:237
 - melatonin, chronic pain, 22:179
 - 3-methoxy-4-hydroxyphenylglycol, panic disorder, 20:13

- Sex differences (cont.)
 monoamine oxidase in plasma, panic disorder, 20:13
 monoamine oxidase in platelets, panic disorder, 20:13
 monoamine oxidase, platelets, 20:129, 20:155, 20:199, 22:37, 22:99
 panic disorder, lactate response, 22:341
- Sleep
 arecoline infusion, rapid eye movement sleep, 22:261
 carbamazepine response, 21:71, 22:11
 deprivation, carbamazepine effect, 22:11
 deprivation, desipramine effect, 21:337
 frequency analysis, affective illness, 21:89
 growth hormone, sleep deprivation, 21:337
 monoamine oxidase inhibition, rapid eye movements, 20:177
 phase shift, mood change in normals, 22:149
 prolactin, sleep deprivation, 21:337
 rapid eye movement sleep, acute sleep delay, 22:149
 sleep deprivation, endogenous depression, 21:95
- Sodium transport
 lithium effect, bipolar affective disorder, 22:49
- Substance abuse
 cocaine craving, bromocriptine, 20:261
 monoamine oxidase, perceptual aberration, 20:129
 paraphernalia, cocaine, 20:261
- Tachycardia (see Heart rate)
- Tardive dyskinesia
 lateralized neuroleptic side effects, evoked potentials, 22:311
- Thyroid-stimulating hormone
 β -adrenoceptor binding, dexamethasone suppression, 20:239
- Thyroid-stimulating hormone (cont.)
 catecholamines, affective illness, 22:127
 depressive symptoms, nursing home, 21:199
 3-methoxy-4-hydroxyphenylglycol, affective illness, 22:21
 neuroleptic effect, borderline personality disorder, 21:307
 prolactin and electroconvulsive therapy, 20:207
- Triiodothyronine
 antidepressant potentiation, rat learned helplessness, 21:267
 borderline personality disorder, neuroleptic effect, 21:307
- Tyramine pressor response
 monoamine oxidase inhibitor, moclobemide, 22:213
- Vanillylmandelic acid
 corticotropin-releasing hormone, affective illness, 20:229
- Ventricular size
 computed tomographic measurement, 22:91
 negative symptoms, neuropsychological scores, 21:137
 schizophrenia, magnetic resonance imaging, 20:33
 schizophrenia, third ventricle, 21:49
 smooth pursuit eye movements, schizophrenia, 21:293
- Weight
 anorexia nervosa, desmethyl-imipramine, 20:19
 clonidine, anorexia nervosa, 20:249
 growth hormone-releasing factor, cerebrospinal fluid, 22:141
- Yohimbine
 affective disorder, platelet binding, 20:107